161 related articles for article (PubMed ID: 7896180)
21. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival.
Ali-Fehmi R; Morris RT; Bandyopadhyay S; Che M; Schimp V; Malone JM; Munkarah AR
Am J Obstet Gynecol; 2005 Mar; 192(3):819-25. PubMed ID: 15746677
[TBL] [Abstract][Full Text] [Related]
22. Cyclin D1 overexpression in primary hypopharyngeal carcinomas.
Masuda M; Hirakawa N; Nakashima T; Kuratomi Y; Komiyama S
Cancer; 1996 Aug; 78(3):390-5. PubMed ID: 8697381
[TBL] [Abstract][Full Text] [Related]
23. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.
Cattoretti G; Becker MH; Key G; Duchrow M; Schlüter C; Galle J; Gerdes J
J Pathol; 1992 Dec; 168(4):357-63. PubMed ID: 1484317
[TBL] [Abstract][Full Text] [Related]
24. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.
Bettencourt MC; Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Moul JW
J Urol; 1996 Sep; 156(3):1064-8. PubMed ID: 8709308
[TBL] [Abstract][Full Text] [Related]
25. Ovarian serous borderline tumors with invasive peritoneal implants.
Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
Brustmann H
Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein.
Domagala W; Markiewski M; Harezga B; Dukowicz A; Osborn M
Clin Cancer Res; 1996 Jan; 2(1):147-54. PubMed ID: 9816101
[TBL] [Abstract][Full Text] [Related]
28. KI67 proliferation index in tumors of the upper urinary tract as related to established prognostic factors and long-term survival.
Rey A; Lara PC; Redondo E; Valdés E; Apolinario R
Arch Esp Urol; 1998 Mar; 51(2):204-10. PubMed ID: 9586325
[TBL] [Abstract][Full Text] [Related]
29. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
30. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
Hogg R; Scurry J; Kim SN; Friedlander M; Hacker N
Gynecol Oncol; 2007 Jul; 106(1):44-51. PubMed ID: 17467045
[TBL] [Abstract][Full Text] [Related]
31. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy.
Bubendorf L; Sauter G; Moch H; Schmid HP; Gasser TC; Jordan P; Mihatsch MJ
J Pathol; 1996 Apr; 178(4):437-41. PubMed ID: 8691323
[TBL] [Abstract][Full Text] [Related]
32. MIB 1 immunostaining in cervical carcinoma of young patients.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; De Nictolis M; Biagini G
Gynecol Oncol; 1997 Nov; 67(2):184-7. PubMed ID: 9367705
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
Brustmann H; Naudé S
Gynecol Oncol; 2002 Jan; 84(1):47-52. PubMed ID: 11748975
[TBL] [Abstract][Full Text] [Related]
35. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.
Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327
[TBL] [Abstract][Full Text] [Related]
36. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
[TBL] [Abstract][Full Text] [Related]
37. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
[TBL] [Abstract][Full Text] [Related]
38. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas.
Jensen V; Sørensen FB; Bentzen SM; Ladekarl M; Nielsen OS; Keller J; Jensen OM
Histopathology; 1998 Jun; 32(6):536-46. PubMed ID: 9675593
[TBL] [Abstract][Full Text] [Related]
39. [Proliferating cell nuclear antigen (PCNA) in ovarian carcinoma and its relation to lymph node metastasis and prognosis].
Wu X; Zhang Z; Cai S
Zhonghua Zhong Liu Za Zhi; 1998 Jan; 20(1):68-70. PubMed ID: 10921065
[TBL] [Abstract][Full Text] [Related]
40. Analysis of relative proliferation rates of Wilms' tumor components using proliferating cell nuclear antigen and MIB-1 (Ki-67 equivalent antigen) immunostaining and assessment of mitotic index.
Khine MM; Aung W; Sibbons PD; Howard CV; Clapham E; McGill F; Van Velzen D
Lab Invest; 1994 Jan; 70(1):125-9. PubMed ID: 7905542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
